Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

BACKGROUND: Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. METHODS: Postmenopausal women with ER-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Wei, Chen, Jiewen, Deng, Heran, Jin, Liang, He, Zhanghai, Rao, Nanyan, Nie, Yan, Yao, Yandan, Yang, Yaping, Su, Fengxi, Liu, Jieqiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317384/
https://www.ncbi.nlm.nih.gov/pubmed/34315439
http://dx.doi.org/10.1186/s12885-021-08612-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317384/
https://www.ncbi.nlm.nih.gov/pubmed/34315439
http://dx.doi.org/10.1186/s12885-021-08612-y

Ejemplares similares